bluuebunny/crossref_metadata_2025_split huggingface dataset:
Treatment trends in gastroesophageal and gastric cancers in the United States.
Authors: Mokdad Ali , Ali Amna , Nassour Ibrahim , Mansour John C. , Wang Sam C. , Porembka Matthew R. 
Published: March 2017

136 Background: Randomized clinical trials reported in the last decade have helped define gastroesophageal junction (GEJ) and gastric cancer (GC) treatment. It is unclear, however, how practice patterns have evolved following these trials. This study explores the trends in treatment of GEJ and GC over the past decade in the United States. Methods: Patients with adenocarcinoma of the stomach and distal esophagus were identified in the National Cancer Database between 2006 and 2013. Tumor located in the distal esophagus and gastric cardia was denoted GEJ. Tumors distal to the cardia constituted GC. Tumors were categorized as early (Stage IA), locally advanced (IB-IIIC), and metastatic (IV). Detailed treatment was compared according to tumor stage and location. A time trend analysis was conducted. Results: A total of 120,729 patients (GEJ: 79,654 [66%], GC: 41,075 [34%]) were identified. Stage was similar in both groups (early: 12%, locally advanced: 55%, and metastatic: 33%). Overall, 73% of early GEJ and 74% of early GC underwent resection; of those, 43% and 12% were local excisions, respectively. Local excisions increased over time in both groups (annual odds ratio [OR] = 1.2; P < 0.01). In locally advanced GEJ, neoadjuvant chemoradiotherapy (CRT) increased among patients that received multimodality treatment (53% in 2006 to 73% in 2013; OR = 1.1, P < 0.01). In locally advanced GC, the use of neoadjuvant chemotherapy (CT) increased (5% to 20%; OR = 1.2, P < 0.01) as did perioperative CT (1% to 9%; OR = 1.3, P < 0.01) in lieu of adjuvant CRT (68% to 43%; OR = 0.9, P < 0.01). Multimodality treatment use remained stable over the study period in both groups (GEJ: 42%, GC: 47%). Among patients with metastatic disease, only 61% of GEJ and 40% of GC patients received CT, with 32% and 40%, respectively, not receiving any therapy at all. Conclusions: Practice patterns for GEJ and GC changed in the last decade with increasing adoption of neoadjuvant therapy in locally advanced disease and local excision of early stage cancers. Treatment for metastatic disease remains markedly underutilized, particularly GC.
A National Cancer Database analysis of treatment utilization and associated outcomes in elderly patients with locally advanced esophageal cancer.
Authors: Vlacich Gregory Riccardo , Samson Pamela Parker , Perkins Stephanie Mabry , Roach Michael Charles , Parikh Parag J. , Bradley Jeffrey D. , Lockhart Albert C. , Puri Varun , Meyers Bryan F , Kozower Benjamin D. , Robinson Cliff Grant 
Published: March 2017

138 Background: Elderly patients with locally advanced esophageal cancer pose a therapeutic challenge since definitive treatment involves aggressive combined-modality therapy. Whether these individuals are offered or benefit from these approaches in the modern, trimodality era has not been widely explored. Methods: Patients ≥ 70 years old with clinical stage II and III esophageal cancer diagnosed between 1998 and 2012 were identified from the National Cancer Database and stratified based on treatment. Variables independently associated with treatment utilization were evaluated using logistic regression and mortality hazard evaluated using Cox-proportional hazards analysis. The primary aim was to compare overall survival by treatment group. The secondary aim was to identify variables associated with receiving each modality. Results: A total of 21,593 patients were identified. Median and maximum ages were 77 and 90 respectively. In 12.9%, no therapy was delivered, 24.3% received palliative therapy, 37.1% received definitive chemoradiation, 5.6% received esophagectomy alone, and 10.0% received trimodality therapy. On multivariate analysis, age ≥ 80 (OR 0.73, p < 0.001), female gender (OR 0.81, p < 0.001), and treatment at high-volume centers (OR 0.83, p = 0.008) were associated with a decreased likelihood of palliative therapy over no treatment. Age ≥ 80 (OR 0.15, p < 0.001), female gender (OR 0.80, p = 0.03), and non-Caucasian race (OR 0.63, p < 0.001) were associated with decreased trimodality use compared to definitive chemoradiation. Each treatment independently demonstrated improved survival compared to no therapy: palliative treatment (HR 0.49), concurrent chemoradiation (HR 0.36), esophagectomy (HR 0.31), trimodality therapy (HR 0.25), all p < 0.001. Conclusions: Any therapy, including palliative care, was associated with improved survival compared to no treatment in elderly patients with esophageal cancer. Subsets of patients are less likely to receive aggressive therapy based on social and institutional factors. Care should be taken to not unnecessarily deprive elderly patients of treatment that may improve survival.
Comparison between local and extended field radiotherapy, including regional nodes radiotherapy, in combination with concurrent chemotherapy for T1bN0M0 esophageal cancer.
Authors: Nakatani Yukihiro , Kato Ken , Shoji Hirokazu , Iwasa Satoru , Honma Yoshitaka , Takashima Atsuo , Hamaguchi Tetsuya , Ito Yoshinori , Itami Jun , Saito Yutaka , Boku Narikazu , Umezawa Rei 
Published: March 2017

142 Background: Extended field (EF) radiotherapy including regional nodes, has been adopted for the treatment of esophageal squamous cell carcinoma (ESCC), but it sometimes causes severe radiation-related adverse events. The purpose of this study is to compare local-field (LF) to EF radiotherapy administered as chemoradiotherapy (CRT) in early esophageal cancer. Methods: Selection criteria included histologically proven T1bN0M0 ESCC, performance status (PS) 0-1, adequate organ function and no other active malignancy. Data on patients who received CRT concurrently with 5-FU and cisplatin between Jan. 2000 and Dec. 2012 in our hospital were evaluated. All patients received radiotherapy at a dose of 60Gy without a planned break. The clinical target volume (CTV) of LF included gross tumor volume (GTV) plus 3-cm superior and inferior margins, and that of EF included GTV plus regional lymph nodes. Overall survivals (OS) were estimated with the Kaplan-Meier method and compared with the log-rank test. The Cox regression model was used for multivariate analysis. Adverse events were graded according to the CTCAE v.4.0. Results: The characteristics of the EF group (n = 120) and LF group (n = 79) are: Median age, 68.0 years and 65.0 years; male/female, 106/14 and 67/12; PS 0/1, 93/27 and 63/18; median tumor length, 40.6mm and 35.4mm, respectively. The complete response rates were 90.0% and 98.7%, respectively. The median follow-up periods were 103 months and 69 months, respectively. The 5-year overall and cause-specific survival rates were 74.5% and 90.6%, 89.5% and 91.8%, respectively. According to a multivariate analysis, EF was a significant negative prognostic factor for OS (hazard ratio = 2.88, p = 0.002) but not for cause-specific survival. Cardiopulmonary toxicities of grade 3 or greater were observed more frequently in the EF group (p = 0.035), with statistical significance. Treatment-related death occurred at 6.7% and 1.3%, respectively, in the two groups. Conclusions: It is suggested that radiation with LF may be better than EF in combination with concurrent chemotherapy in early esophageal cancer (T1bN0M0).
Outcomes of locoregional therapy for metastatic gastric cancer.
Authors: Shridhar Ravi , Huston Jamie , Meredith Kenneth L 
Published: March 2017

143 Background: Patients with metastatic gastric cancer have poor survival. The purpose of this study was to compare outcomes of metastatic gastric cancer patients with or without surgery and radiation therapy (RT). Methods: The National Cancer Database (NCDB) was accessed to identify patients with stage IV gastric cancer between 2004 and 2013 and stratified by surgery. Propensity score matching was performed against age, metastatic site, radiation, and signet ring histology. Overall survival (OS) analysis was determined by Kaplan-Meier and log-rank analysis. Multivariate analysis (MVA) was analyzed by the Cox proportional hazard ratio model. Results: A total of 1808 patients were identified. Surgery was associated with an OS benefit. Median and 5-year OS for surgery and no surgery was 16 months and 16% and 10 months and 2%, respectively (p < 0.001). Median and 5 year OS for patients treated with surgery and RT was 22.4 months and 26%. Median and 5 year OS for surgery patients treated with or without preoperative RT was 27.2 months and 28% and 15.2 months and 12%, respectively (p < 0.001). There was no OS benefit with postoperative RT. MVA for all patients revealed that surgery and tumor location were associated with decreased mortality while peritoneal metastases were associated with increased mortality. In surgical patients, MVA showed that RT, partial esophagectomy, and tumor location were associated with decreased mortality, while positive margins, signet ring histology, and peritoneal metastases were associated with increased mortality. In nonsurgical patients, only carcinomatosis was prognostic on MVA. Conclusions: Surgery and radiation are associated with increased survival in a subset of patients with metastatic gastric cancer. Prospective trials will be needed to address the role and sequence of surgery and radiation in metastatic gastric cancer.
Comparison of long-term outcomes of endoscopic submucosal dissection and surgery for esophagogastric junction adenocarcinoma.
Authors: Kim Do Hoon , Gong Eun Jeong , Ahn Ji Yong , Jung Kee Wook , Lee Jeong Hoon , Choi Kee Don , Song Ho June , Lee Gin Hyug , Jung Hwoon-Yong , Lee In-Seob , Kim Beom Su , Yoo Moon-Won , Oh Sung Tae , Yook Jeong Hwan , Kim Byung Sik 
Published: March 2017

144 Background: Endoscopic submucosal dissection (ESD) has been accepted as standard treatment for early gastric cancer. However, comparative outcomes of ESD and surgery have not been evaluated for adenocarcinoma in the esophagogastric junction (EGJ). We investigated the long-term outcomes of ESD compared with surgery for adenocarcinoma in the EGJ. Methods: Subjects who underwent ESD or surgery for Siewert type II adenocarcinoma which met absolute and expanded criteria between 2005 and 2010 were eligible for this study. Clinical features and treatment outcomes were retrospectively reviewed using medical records. Results: Among 79 patients included, 40 underwent ESD and 39 underwent surgery. During the median follow-up period of 60.9 months (range: 13.1-125.4 months), the 5-year overall survival rates were 93.9% and 97.3% for ESD and surgery groups, respectively ( p= 0.376). There was no gastric cancer-related deaths in either groups. Adverse events occurred in 11 patients (13.9%) overall and the incidence of treatment-related adverse events was similar between two groups (10.0% vs. 17.9%, p= 0.308). Conclusions: ESD may be an effective alternative to surgery for the treatment of early gastric cancer in the EGJ, based on comparable long-term outcomes.
Patterns of treatment and outcomes in elderly patients with non-metastatic, unresected gastric adenocarcinoma: A review of the Florida cancer data system.
Authors: Vlacich Gregory Riccardo , Samson Pamela Parker , Stowe Hayley , Hsieh Samantha , Robinson Cliff Grant , Perkins Stephanie Mabry 
Published: March 2017

146 Background: Concurrent chemoradiation is considered definitive treatment for unresected, localized gastric adenocarcinoma, but utilization in the elderly is complicated by increased toxicity risk and limited life expectancy. The benefit of concurrent chemoradiation in this population over non-definitive therapy is not well characterized. Methods: The Florida Cancer Data System was queried for patients ≥ 60 years old diagnosed with non-metastatic gastric adenocarcinoma between 2004 and 2010 who did not undergo primary surgery. Logistic regression was performed to evaluate variables independently associated with treatment and mortality hazard was evaluated using Cox-proportional modeling. The primary aim was to compare overall survival between groups. Results: A total of 1,729 patients were identified with a median and maximum age of 79 and 101 years respectively. The majority received no therapy (68.4%) followed by concurrent chemoradiation (12.0%), chemotherapy alone (10.5%), radiation alone (5.0%), and sequential chemoradiation (4.2%). Median survival with no treatment was 3.7 months (95% CI: 3.3-4.1) and no difference was seen with radiation alone (MS 5.4 months, p = 0.85). However, improved survival was seen with chemotherapy alone (9.1 months), and concurrent (10.5 months) and sequential (12.5 months) chemoradiation, all p < 0.001 compared to no therapy. Despite a modest survival benefit with sequential chemoradiation compared to chemotherapy alone (p = 0.046), this was not seen with concurrent chemoradiation (p = 0.215) or between concurrent and sequential chemoradiation (p = 0.266). On multivariate analysis, age ≥ 80 (OR 0.41, p < 0.001) and African-America race (OR 0.45, p = 0.004) were independently associated with no treatment compared to receiving any chemotherapy. Conclusions: Chemotherapy may improve survival over those not receiving systemic therapy, and the addition of radiation does not appear to provide any added benefit over chemotherapy alone. Advanced age and African-American race are strong predictors against chemotherapy use, however additional factors not accounted for such as performance status may contribute.
Trends in multimodality therapy for gastric cancer post-MAGIC.
Authors: Sada Yvonne , Smaglo Brandon George , Tran Cao Hop Sanderson , Akce Mehmet , Mok Henry , Musher Benjamin Leon , Massarweh Nader Nabile 
Published: March 2017

148 Background: Althoughmultimodality therapy (MMT) is recommended for most patients with resectable gastric cancer, no single approach has been established as standard. As such, little is known about current national practice patterns and MMT treatment sequencing for patients with gastric cancer. Methods: This was a retrospective cohort study of ≥ T2 and/or node positive gastric cancer patients treated with MMT using the National Cancer Database (2006-2012). Patients were categorized based on type of MMT (chemotherapy, concurrent chemoradiation (cXRT), or both chemotherapy and cXRT) and treatment sequence (preoperative, postoperative, or perioperative). Accuracy of pre-treatment clinical nodal staging was ascertained by comparison to pathologic nodal staging in patients treated with upfront surgery. Multivariable Cox regression was used to evaluate the association between overall risk of death and MMT type and sequence. Results: Among 4,857 patients, 14.1% were treated perioperatively, 48.0% preoperatively, and 37.9% postoperatively. Rates of chemotherapy, cXRT, and both chemotherapy and cXRT were 32.1%, 53.4%, and 14.5%. Among patients treated with upfront surgery, sensitivity, specificity, PPV, and NPV of clinical nodal staging were 70.7%, 88.8%, 92.1%, and 62.2%, respectively. Over the study period, use of cXRT decreased (61.8% 2006 vs 52.0% 2012; trend test, p < 0.001) while use of chemotherapy increased (23.6% vs 35.7%; trend test, p < 0.001) and use of both chemotherapy and cXRT did not change. There was an increase in the use of perioperative treatment (8.1% vs 17.4%; trend test, p < 0.001) while postoperative treatment decreased (44.4% vs 31.1%; trend test, p < 0.001). After multivariable modeling, neither type of MMT nor treatment sequence was associated with risk of death. Conclusions: Although current national practice patterns favor pre- and perioperative treatment, one third of patients were treated with upfront surgery. Survival was not associated with MMT type or sequence. However, given the high false negative rate of clinical nodal staging and high non-completion rate of postoperative treatment (50% in MAGIC trial), efforts to improve gastric cancer outcomes should focus on increasing use of preoperative therapy.
Phase II study of trastuzumab with irinotecan in HER2-positive metastatic or advanced gastric cancer patients previously treated with trastuzumab and failed: HGCSG 1201/OGSG1205.
Authors: Kawamoto Yasuyuki , Meguro Takashi , Yuki Satoshi , Nakatsumi Hiroshi , Sasaki Takahide , Hatanaka Kazuteru , Uebayashi Minoru , Iwanaga Ichiro , Abe Nobuhiko , Nakamura Michio , Okuda Hiroyuki , Eto Kazunori , Oba Ayane , Abe Masakazu , Oba Koji , Satoh Taroh , Sakata Yuh , Sakamoto Naoya , Komatsu Yoshito ,   Hokkaido Gastrointestinal Cancer Study Group
Published: March 2017

151 Background: Some phase II and III studies of second-line chemotherapy for metastatic or advanced gastric cancer have been reported in recent years. Irinotecan is one of the standard regimen for second-line therapy. On the other hand, the efficacy of continuing trastuzumab (Tmab) beyond progression in patients (pts) who had previously been treated with Tmab plus standard first line chemotherapy has not been reported. We conducted this study to assess the efficacy and safety of Tmab with irinotecan in HER2-positive gastric cancer pts previously treated with Tmab (UMIN ID: 000007636). Methods: Patients with HER2-positive metastatic or advanced gastric cancer who were previously treated with Tmab and failed were included. Pts received Tmab every 3 weeks and irinotecan every 2 weeks. Primary endpoint was response rate (RR), and secondary endpoints were progression-free survival (PFS), six-month survival rate, safety, sub-group analysis by HER2 status (IHC 3+ group, IHC 2+/FISH positive group), and so on. Results: Only 16 pts were enrolled from 9 institutions in three years during a pre-planned registration period. We stopped this study on the way, unfortunately. In a total of 16 pts, one patient was excluded and 15 were analyzed. Median age was 65, male/female; 9/6, ECOG PS 0/1; 8/7, and IHC 3+/IHC 2+ and FISH positive; 10/5, respectively. Response rate was 7% and disease control rate was 53%. Median PFS and overall survival (OS) were 2.4 (95%C.I.; 0.0-5.2 months) and 9.7 months (95%C.I.; 8.2-11.2 months), respectively. Six-month PFS rate was 13%. In sub-group analysis by HER2 status, median PFS of IHC 3+ and IHC 2+/FISH positive were 2.2 and 2.4 months, respectively. Median OS of each groups were 8.8 and 10.8 months. The most frequently reported grade 3-4 adverse events were neutropenia (40%), anemia (27%), anorexia (33%), and fatigue (33%). Conclusions: This study was closed prematurely due to poor accrual. It seemed that continued use of Tmab and irinotecan beyond disease progression has not significant clinical benefit in HER2-positive metastatic or advanced gastric cancer pts previously treated with Tmab. Clinical trial information: UMIN000007636.
Efficacy and safety of taxane-monotherapy in advanced gastric cancer refractory to triplet chemotherapy with docetaxel, cisplatin, and S-1: A multicenter retrospective study.
Authors: Kawai Sadayuki , Iizumi Sakura , Takashima Atsuo , Narita Yukiya , Tajika Masahiro , Matsushima Tomohiro , Yasui Hirofumi , Muro Kei , Takahari Daisuke , Boku Narikazu 
Published: March 2017

154 Background: While taxane-monotherapy following fluoropyrimidine plus platinum is recognized as the standard treatment strategy for advanced gastric cancer, triplet chemotherapy with docetaxel, cisplatin and S-1 (DCS) is another option for first-line therapy in Japan. However, efficacy of taxane after DCS therapy has not been sufficiently evaluated. Methods: We retrospectively evaluated the efficacy and safety of taxane-monotherapy after DCS between January 2010 and April 2015 for advanced gastric cancer. The taxane-monotherapy included weekly paclitaxel (PTX) (80 mg/m2, day 1, 8 and 15 of a 28-day cycle) and triweekly nab-PTX (260 mg/m2, day 1). Other selection criteria were: ECOG PS < 2; adequate organ function; no severe ascites; HER2-negative. Results: Thirty of 92 patients who had been treated with DCS received taxane-monotherapy. Fifteen and 15 patients received taxane-monotherapy as the second and third-line treatment, respectively. Patients characteristics of each group (2nd/3rd) were; median age: 64/62 (range 27-75/42-75); ECOG PS ≤ 1: 14/13; number of metastatic sites ≥ 2: 9/12; median taxane-free interval from first-line treatment: 1.6/3.4 (range 0.9-2.3/2.2-8.3) months; median total dose of prior DTX: 349/208 (range 39-844/141-685) mg/m2. Number of patients who received PTX/nab-PTX were 10/5 and 13/2 in the second and third line treatment. Median relative dose intensity of taxane was 96.4% (range 57.6-172.9%) in the second-line, 98.5% (44.0-166.8%) in the third-line group. Response rate and disease control rate were 0% and 37.5% in the second-line, and 0% and 38.5% in the third-line group. Median progression free survival and overall survival were 3.4 and 5.8 months in the second-line group, and 2.0 and 4.5 months in the third-line. Grade 3 or 4 neutropenia, anemia, and anorexia, occurred in 33%, 13% and 13% in the second-line group, and 6.7%, 13% and 6.7% in the third–line group, associated with no treatment related death. Conclusions: It is suggested that taxane-monotherapy has acceptable toxicities but insufficient efficacy in advanced gastric cancer patients after DCS therapy.
The prognostic factors for advanced gastric cancer with para-aortic nodal involvement after extended gastrectomy.
Authors: Kaito Akio , Kinoshita Takahiro , Sunagawa Hideki , Sugita Shizuki , Watanabe Masahiro , Terada Mitsumi 
Published: March 2017

158 Background: The prognosis of patients with advanced gastric cancer with para-aortic lymph node (PAN) involvement is poor. We retrospectively investigated the prognostic factors for advanced gastric cancer with PAN involvement. Methods: The patients who underwent radical gastrectomy with PAN dissection for advanced gastric cancer between 1992 and 2014 in our institution included in this study. The clinicopathological features and prognostic factors of the patients who identified pathologically PAN involvement after curative gastrectomy were analyzed. Results: In this period, a total of 704 patients underwent gastrectomy with PAN dissection and 65 patients were identified as pathologically PAN positive and eligible for this study. Total gastrectomy and combined resection of other organs were performed for 48 patients and 51 patients, respectively. Complete PAN dissection (a2/b1) was performed for 32 patients. Postoperative abdominal complication was 20% with no hospital deaths. The 3 year and the 5 year overall survival (OS) were 33.8% and 21.2%, respectively. Multivariate cox regression analysis revealed nodal involvement (any of the station No.8a, No.9 and No.11; hazard ratio, 4.04; 95% confidence interval, 1.55-10.5), tumor diameter (over 120mm; HR, 3.37; 95%CI, 1.18-9.63) and total number of PAN involvement (over 2 nodes; HR, 2.24; 95%CI, 1.21-4.15) were poor prognostic factor. The patients without these poor prognostic factors had survived significantly longer than the patient with any of these factors in Kaplan-meier analysis (the 5 year OS: 87.5% vs 9.4%, P <0.001). Conclusions: Tumor size, nodal involvement of the station No.8a, No.9 and No.11 and total number of PAN involvement were poor prognostic factors for advanced gastric cancer with PAN involvement. The candidates for extensive nodal dissection for advanced gastric cancer should carefully be selected.